Both CD44-targeted NIR-PIT and combination groups showed significantly smaller tumor volume than CTLA4 mAb group at 2, 5, 7, 10, 12, and 14 days after NIR-PIT (p < 0.05, Tukey–Kramer test) (Figure 3H). This evidence concerns the gene CD44 and neoplasm.